{
  "id": 2873797,
  "title": "Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run",
  "url": "https://urgent.news/2026/08/23/axsome-therapeutics-stock-is-up-16-year-to-date-why-wall-street",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-23T21:00:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/08/23/axsome-therapeutics-stock-is-up-16-year-to-date-wh/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Axsome Therapeutics (NASDAQ: AXSM) has shown impressive growth this year, with its shares soaring 16% compared to the S&P 500's 11% increase. Analysts are optimistic about the biotech company's potential, with an average price target of $285.42 set by Yahoo! Finance, suggesting a 37% upside from its present valuation.\n\nThe positive outlook stems from Axsome Therapeutics' significant clinical and regulatory advancements in recent years. The company secured approval for Auvelity as a treatment for depression and later expanded the medication's usage for managing Alzheimer's disease (AD) agitation. Additionally, Axsome Therapeutics boasts a portfolio of other approved products, including Symbravo for migraine therapy and Sunosi for daytime sleepiness associated with narcolepsy.\n\nThe company's revenue has been on a rapid growth trajectory. During the second quarter, Axsome Therapeutics' earnings surged 46% year-over-year, reaching $218.4 million. Auvelity, the primary growth catalyst, drives this upward trend.",
  "summary": "The company has also crushed broader equities over the past five years.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run",
        "url": "https://urgent.news/2026/08/23/axsome-therapeutics-stock-is-up-16-year-to-date-why-wall-street-2875435",
        "published": "2026-08-23T21:20:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}